Scott Terrillion insider trades: Cara Therapeutics (CARA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Scott reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | CARA | ↓ Sell | 163 | $4.76 | $776 | Direct | Mar 4, 2025 (4d) |
| Apr 5, 2024 | CARA | ↓ Sell | 2,753 | $0.83 | $2K | Direct | Apr 9, 2024 (4d) |
| Feb 29, 2024 | CARA | ↓ Sell | 3,293 | $0.89 | $3K | Direct | Mar 4, 2024 (4d) |
| Jun 23, 2023 | CARA | ↓ Sell | 2,483 | $3.51 | $9K | Direct | Jun 27, 2023 (4d) |
| Apr 4, 2023 | CARA | ↓ Sell | 2,481 | $4.91 | $12K | Direct | Apr 6, 2023 (2d) |
| Mar 3, 2023 | CARA | ↓ Sell | 6,256 | $9.71 | $61K | Direct | Mar 7, 2023 (4d) |
| Feb 8, 2023 | CARA | ↓ Sell | 7,770 | $0.53 | $4K | Direct | Feb 12, 2024 (369d) |
| Dec 21, 2022 | CARA | ↓ Sell | 2,561 | $11.27 | $29K | Direct | Dec 23, 2022 (2d) |
| Apr 1, 2022 | CARA | ↓ Sell | 1,642 | $11.91 | $20K | Direct | Apr 5, 2022 (4d) |
| Mar 3, 2022 | CARA | ↓ Sell | 1,787 | $11.38 | $20K | Direct | Mar 4, 2022 (1d) |
| Feb 25, 2022 | CARA | ↓ Sell | 1,972 | $10.29 | $20K | Direct | Mar 1, 2022 (4d) |
| Aug 30, 2021 | CARA | ↓ Sell | 1,759 | $14.20 | $25K | Direct | Sep 1, 2021 (2d) |
| Mar 5, 2021 | CARA | ↓ Sell | 3,090 | $17.98 | $56K | Direct | Mar 8, 2021 (3d) |
| Feb 25, 2021 | CARA | ↓ Sell | 4,004 | $19.33 | $77K | Direct | Feb 25, 2021 (0d) |
| Dec 30, 2020 | CARA | ↓ Sell | 1,946 | $15.30 | $30K | Direct | Dec 30, 2020 (0d) |
| Apr 21, 2020 | CARA | ↓ Sell | 2,721 | $15.56 | $42K | Direct | Apr 21, 2020 (0d) |
| Dec 4, 2019 | CARA | ↓ Sell | 3,980 | $17.05 | $68K | Direct | Dec 4, 2019 (0d) |
| May 29, 2019 | CARA | ↓ Sell | 2,303 | $21.38 | $49K | Direct | May 30, 2019 (1d) |
| Dec 28, 2018 | CARA | ↓ Sell | 3,100 | $12.51 | $39K | Direct | Jan 2, 2019 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Scott Terrillion's insider trades
Scott Terrillion is Sec'Y; Chief Compliance & G.C. at Cara Therapeutics (CARA). Since Dec 28, 2018, Scott has reported no open-market purchases and 19 sales worth $567K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (16 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CARA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.